Endocyte Inc (ECYT) 6.38 $ECYT
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 39.32 (+0.67), PERI: 5.62 (-0.15), UNXL: 5.32 (-0.05), TREE: 46.32 (-0.57), SSRI: 5.87 (+0.44), STMP: 46.42 (+0.05), RPRX: 9.19 (-0.14), NYNY: 7.49 (+0.21), SHLD: 35.91 (+0.29), AREX: 11.19 (-0.38), PGNX: 6.54 (+0.15), ECYT: 6.38 (-0.03), SSO.TO: 6.63 (+0.52), SGMA: 7.33 (+0.05), SW.TO: 44.45 (+0.78), PLNR: 7.39 (+0.34)
Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 6.38 (-0.03), AUXL: 32.69 (+0.51), ADHD: 3.24 (-0.21), BIOD: 1.61 (+0.02)
Endocyte's (ECYT) CEO Ron Ellis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:52PM CST
ECYT: 6.38 (-0.03)
Endocyte beats 3Q profit forecasts
Automated Insights - Wed Nov 05, 6:27PM CST
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a third-quarter loss of $5.7 million.
ECYT: 6.38 (-0.03)
Endocyte (ECYT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ECYT: 6.38 (-0.03)
Endocyte beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:22PM CST
ECYT: 6.38 (-0.03)
Endocyte Reports Third Quarter Financial Results and Provides Clinical Update
GlobeNewswire - Wed Nov 05, 3:01PM CST
Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide
ECYT: 6.38 (-0.03)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST
CXO: 114.98 (+0.85), CODI: 16.98 (+0.15), EXXI: 6.59 (-0.24), JCOM: 55.68 (+0.30), ATSG: 7.92 (+0.08), GPOR: 51.96 (-0.20), ENS: 60.40 (+0.50), ECYT: 6.38 (-0.03), ALNY: 89.95 (+0.97), KGC: 2.96 (+0.25), GSM: 17.73 (-0.02), BKD: 34.28 (+0.46), DK: 31.17 (+0.85), AR: 52.15 (-0.12), IL: 10.46 (+0.13), DVR: 0.14 (-0.08), IO: 2.65 (+0.03), DEPO: 15.41 (+0.08), ETE: 64.48 (+1.77), AVG: 18.89 (-0.12), CSOD: 30.57 (+0.36), GNW: 9.36 (+0.03), ECOL: 39.42 (-0.17), BWC: 29.98 (-0.18), CPE: 6.01 (-0.04), FNV: 56.32 (+2.46), CTL: 41.09 (+0.14), ASH: 111.82 (+2.71), ENSG: 39.17 (+0.10), CLR: 52.64 (+0.01), ACAS: 14.87 (-0.12), G: 17.91 (-0.03), BREW: 13.79 (-0.06), AWK: 52.34 (+0.37), CVG: 21.01 (+0.05), AREX: 11.19 (-0.38), HTCH: 3.51 (-0.05), ETP: 67.39 (-0.13), ABTL: 11.08 (+0.34), FMI: 25.86 (+0.66), DPM: 52.27 (+0.52), BCOR: 14.00 (-0.23), CDE: 4.70 (+0.34), DRYS: 1.43 (+0.02), KW: 26.07 (-0.13), BALT: 3.28 (-0.06), ATO: 53.42 (-0.05), EXAR: 8.64 (+0.06), ACLS: 2.19 (+0.02), INWK: 7.21 (-0.10), ALSK: 1.30 (-0.02), CF: 269.69 (-0.32), EFC: 21.81 (+0.12), BIOS: 5.85 (+0.07), DYN: 33.95 (-0.01), DATA: 82.10 (-1.21), ANDE: 54.48 (+0.28), HOLX: 26.64 (+0.27), CBS: 52.54 (-0.34)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 269.60 (+21.66), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43), HSP: 59.72 (+1.32)
Endocyte to Present at the 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Tue Nov 04, 3:01PM CST
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman, chief financial and operating officer of Endocyte, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, Nov.11, at 8:00 a.m. MT (10:00 a.m. ET). The conference will be held at The Biltmore Hotel in Phoenix, Arizona.
ECYT: 6.38 (-0.03)
Endocyte reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:37PM CDT
ECYT: 6.38 (-0.03)
Endocyte Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update.
ECYT: 6.38 (-0.03)
Equities Updates on Pharma Industry - Mylan, Horizon Pharma, Hospira, VIVUS, and Endocyte
PR Newswire - Tue Oct 21, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), VIVUS Inc. (NASDAQ: VVUS), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 20, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,399.67, up 0.12% and the NASDAQ Composite closed at 4,316.07, up 1.35%. The S&P 500 finished the session 0.91% higher at 1,904.01. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 716.35, up 1.20%, with the index gaining 11.53% on YTD basis. Register for your complimentary reports on these five stocks at:
ECYT: 6.38 (-0.03), VVUS: 3.04 (-0.07), HZNP: 12.85 (+0.35), MYL: 56.24 (+1.11), HSP: 59.72 (+1.32)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 85.45 (+2.35), ARQL: 1.28 (+0.04), BMY: 58.70 (+0.27), GSK: 46.28 (+0.40), ONTY: 1.71 (-0.01), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43), AEZS: 0.55 (unch), GALE: 1.84 (+0.03), NVS: 95.58 (+1.20), XLRN: 33.33 (+0.13), KPTI: 40.71 (-0.07)
Commit To Purchase Endocyte At $5, Earn 34.1% Annualized Using Options
StockOptionsChannel.com - Thu Oct 02, 10:29AM CDT
Investors considering a purchase of Endocyte Inc shares, but tentative about paying the going market price of $5.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
ECYT: 6.38 (-0.03)
Why Endocyte (ECYT) Stock Is Declining Today
at The Street - Tue Sep 30, 10:44AM CDT
Endocyte (ECYT) shares are down after being downgraded to 'hold' by analysts at Brean Capital.
ECYT: 6.38 (-0.03)
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
LCI: 46.70 (+0.06), ENDP: 69.51 (+2.45), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43)
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 39.32 (+0.67), PERI: 5.62 (-0.15), UNXL: 5.32 (-0.05), TREE: 46.32 (-0.57), SSRI: 5.87 (+0.44), STMP: 46.42 (+0.05), RPRX: 9.19 (-0.14), NYNY: 7.49 (+0.21), SHLD: 35.91 (+0.29), AREX: 11.19 (-0.38), PGNX: 6.54 (+0.15), ECYT: 6.38 (-0.03), SSO.TO: 6.63 (+0.52), SGMA: 7.33 (+0.05), SW.TO: 44.45 (+0.78), PLNR: 7.39 (+0.34)
Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 6.38 (-0.03), AUXL: 32.69 (+0.51), ADHD: 3.24 (-0.21), BIOD: 1.61 (+0.02)
Endocyte's (ECYT) CEO Ron Ellis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:52PM CST
ECYT: 6.38 (-0.03)
Endocyte beats 3Q profit forecasts
Automated Insights - Wed Nov 05, 6:27PM CST
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a third-quarter loss of $5.7 million.
ECYT: 6.38 (-0.03)
Endocyte (ECYT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:25PM CST
ECYT: 6.38 (-0.03)
Endocyte beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:22PM CST
ECYT: 6.38 (-0.03)
Endocyte Reports Third Quarter Financial Results and Provides Clinical Update
GlobeNewswire - Wed Nov 05, 3:01PM CST
Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide
ECYT: 6.38 (-0.03)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:35PM CST
CXO: 114.98 (+0.85), CODI: 16.98 (+0.15), EXXI: 6.59 (-0.24), JCOM: 55.68 (+0.30), ATSG: 7.92 (+0.08), GPOR: 51.96 (-0.20), ENS: 60.40 (+0.50), ECYT: 6.38 (-0.03), ALNY: 89.95 (+0.97), KGC: 2.96 (+0.25), GSM: 17.73 (-0.02), BKD: 34.28 (+0.46), DK: 31.17 (+0.85), AR: 52.15 (-0.12), IL: 10.46 (+0.13), DVR: 0.14 (-0.08), IO: 2.65 (+0.03), DEPO: 15.41 (+0.08), ETE: 64.48 (+1.77), AVG: 18.89 (-0.12), CSOD: 30.57 (+0.36), GNW: 9.36 (+0.03), ECOL: 39.42 (-0.17), BWC: 29.98 (-0.18), CPE: 6.01 (-0.04), FNV: 56.32 (+2.46), CTL: 41.09 (+0.14), ASH: 111.82 (+2.71), ENSG: 39.17 (+0.10), CLR: 52.64 (+0.01), ACAS: 14.87 (-0.12), G: 17.91 (-0.03), BREW: 13.79 (-0.06), AWK: 52.34 (+0.37), CVG: 21.01 (+0.05), AREX: 11.19 (-0.38), HTCH: 3.51 (-0.05), ETP: 67.39 (-0.13), ABTL: 11.08 (+0.34), FMI: 25.86 (+0.66), DPM: 52.27 (+0.52), BCOR: 14.00 (-0.23), CDE: 4.70 (+0.34), DRYS: 1.43 (+0.02), KW: 26.07 (-0.13), BALT: 3.28 (-0.06), ATO: 53.42 (-0.05), EXAR: 8.64 (+0.06), ACLS: 2.19 (+0.02), INWK: 7.21 (-0.10), ALSK: 1.30 (-0.02), CF: 269.69 (-0.32), EFC: 21.81 (+0.12), BIOS: 5.85 (+0.07), DYN: 33.95 (-0.01), DATA: 82.10 (-1.21), ANDE: 54.48 (+0.28), HOLX: 26.64 (+0.27), CBS: 52.54 (-0.34)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 269.60 (+21.66), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43), HSP: 59.72 (+1.32)
Endocyte to Present at the 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Tue Nov 04, 3:01PM CST
Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman, chief financial and operating officer of Endocyte, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, Nov.11, at 8:00 a.m. MT (10:00 a.m. ET). The conference will be held at The Biltmore Hotel in Phoenix, Arizona.
ECYT: 6.38 (-0.03)
Endocyte reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:37PM CDT
ECYT: 6.38 (-0.03)
Endocyte Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update.
ECYT: 6.38 (-0.03)
Equities Updates on Pharma Industry - Mylan, Horizon Pharma, Hospira, VIVUS, and Endocyte
PR Newswire - Tue Oct 21, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), VIVUS Inc. (NASDAQ: VVUS), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, October 20, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,399.67, up 0.12% and the NASDAQ Composite closed at 4,316.07, up 1.35%. The S&P 500 finished the session 0.91% higher at 1,904.01. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 716.35, up 1.20%, with the index gaining 11.53% on YTD basis. Register for your complimentary reports on these five stocks at:
ECYT: 6.38 (-0.03), VVUS: 3.04 (-0.07), HZNP: 12.85 (+0.35), MYL: 56.24 (+1.11), HSP: 59.72 (+1.32)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 85.45 (+2.35), ARQL: 1.28 (+0.04), BMY: 58.70 (+0.27), GSK: 46.28 (+0.40), ONTY: 1.71 (-0.01), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43), AEZS: 0.55 (unch), GALE: 1.84 (+0.03), NVS: 95.58 (+1.20), XLRN: 33.33 (+0.13), KPTI: 40.71 (-0.07)
Commit To Purchase Endocyte At $5, Earn 34.1% Annualized Using Options
StockOptionsChannel.com - Thu Oct 02, 10:29AM CDT
Investors considering a purchase of Endocyte Inc shares, but tentative about paying the going market price of $5.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
ECYT: 6.38 (-0.03)
Why Endocyte (ECYT) Stock Is Declining Today
at The Street - Tue Sep 30, 10:44AM CDT
Endocyte (ECYT) shares are down after being downgraded to 'hold' by analysts at Brean Capital.
ECYT: 6.38 (-0.03)
Endocyte's TARGET Interim Data Positive for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 4:25PM CDT
Endocyte, Inc. (ECYT) announced an encouraging interim update on overall survival (OS) of patients in the phase IIb TARGET study on vintafolide for NSCLC.
LCI: 46.70 (+0.06), ENDP: 69.51 (+2.45), ECYT: 6.38 (-0.03), MRK: 59.89 (+0.43)
